Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome

Expert Opinion on Emerging Drugs

Volumn 17, Issue 1, 2012, Pages 1-4

  Yamashita, Cory M ^a   Lewis, James F ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

acute lung injury; acute respiratory distress syndrome; inflammation; mechanical ventilation

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CISATRACURIUM; DILMAPIMOD; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ROSUVASTATIN; SIMVASTATIN;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; DRUGS, INVESTIGATIONAL; HUMANS; MULTIPLE ORGAN FAILURE; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY SYSTEM AGENTS;

EID: 84858953826     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.667800     Document Type: Review

References (15)

1. Bernard GR, Artigas A, Brigham KL, et al. Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensive Care Med 1994;20(3):225-32 (Pubitemid 24088590)
2. Spragg RG, Bernard GR, Checkley W, et al. Beyond mortality: future clinical research in acute lung injury. Am J Respir Crit Care Med 2010;181(10):1121-7
3. Bosma KJ, Lewis JF. Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs 2007;12(3):461-77 A comprehensive review of emerging therapies and clinical trials for ARDS. (Pubitemid 47518379)
4. Browers R, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The acute respiratory distress syndrome network. N Engl J Med 2000;342(18):1301-8 A landmark trial demonstrating the beneficial effects of low-tidal volume ventilation for patients with ARDS.
5. Available from: http://www.oscillatetrial. com
6. Available from: http://www.clinicaltrials. gov
7. Craig TR, Duffy MJ, Shyamsundar M, et al. A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med 2011;183(5):620-6
8. Rice TW, Wheeler AP. Thompson BT, deBoisblanc BP, Steingrub J, Rock P. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA 2011;306(14):1574-81
9. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010;363(12):1107-16
10. Matthay MA, Brower RG, Carson S, et al. Randomized, placebo-controlled clinical trial of an aerosolized beta-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011;184(5):561-8
11. Gao SF, Perkins GD, Gates S, et al. Effect of intravenous beta-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 2012;379(9812):229-35
12. Paine R III, Standiford TJ, Dechert RE, et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 2012;40(1):90-7
13. Slutsky AS. Neuromuscular blocking agents in ARDS. N Engl J Med 2010;363(12):1176-80
14. Gajic O, Dabbagh O, Park PK, et al. Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med 2011;183(4):462-70
15. Kor DJ, Erlich J, Gong MN, et al. Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med 2011;39(11):2393-400